CCA
REGN icon

Castle Creek Arbitrage’s Regeneron Pharmaceuticals REGN Stock Holding History

Castle Creek Arbitrage’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,000
Closed -$7.75M – 54
2017
Q1 		$7.75M Buy
+20,000
New +$7.41M 0.74% 18

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Castle Creek Arbitrage's REGN Position: Q2 2017 in Review

Castle Creek Arbitrage sold out of Regeneron Pharmaceuticals (REGN) in Q2 2017, closing a stake of 5,200 shares — an estimated $2.02M sold.

Castle Creek Arbitrage first reported a position in REGN in Q1 2017 and held it in 1 quarter. The position peaked at $2.02M in Q1 2017. 603 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

  • Castle Creek Arbitrage reported no remaining Regeneron Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Castle Creek Arbitrage sold 5,200 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $2.02M.
  • Castle Creek Arbitrage first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Castle Creek Arbitrage's Regeneron Pharmaceuticals position peaked at $2.02M in Q1 2017.
  • 603 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on Castle Creek Arbitrage's 13F filing for Q2 2017, filed 3 Aug 2017.